‘Suspect molecular signature-in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention

详细信息    查看全文

• 作者：Manuel Debald (1) (2)
  Kristina Yeghiazaryan (2) (3)
  Melanie Cebioglu (2) (3)
  Walther Kuhn (1) (2)
  Hans H Schild (2) (3)
  Olga Golubnitschaja (2) (3)
  
• 关键词：Breast cancer risk assessment ; Cancer predisposition ; Molecular pattern ; Economy ; Ethics ; Predictive diagnostics ; Preventive health care
• 刊名：The EPMA Journal
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：4
• 期：1
• 全文大小：231 KB
• 参考文献：1. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, Kuhn W, Schild HH: Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? / EPMA J 2013, 4:6. CrossRef
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. / CA Cancer J Clin 2009, 59:225-49. CrossRef
  3. National Cancer Institute at the National Institutes of Health: Breast cancer. http://www.cancer.gov/cancertopics/types/breast
  4. Hillner BE, Smith TJ: Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. / J Clin Oncol 2009, 27:2111-113. CrossRef
  5. Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Qin A, Oster G: Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. / BMC Cancer 2011, 11:250. CrossRef
  6. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. / Clin Cancer Res 2004, 10:6897-904. CrossRef
  7. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. / N Engl J Med 2004, 351:781-91. CrossRef
  8. Pantel K, Muller V, Auer M, Nusser N, Harbeck N, Braun S: Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. / Clin Cancer Res 2003, 9:6326-334.
  9. Hayashi N, Yamauchi H: Role of circulating tumor cells and disseminated tumor cells in primary breast cancer. / Breast Cancer 2012, 19:110-17. CrossRef
  10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. / Lancet 2005, 365:1687-717. CrossRef
  11. Ross JS, Hortobagyi GN: / Molecular Oncology of Breast Cancer. Boston: Jones & Bartlett; 2004.
  12. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN, Yu D: Breast cancer metastasis: challenges and opportunities. / Cancer Res 2009, 69:4951-953. CrossRef
  13. Braun M, Fountoulakis M, Yeghiazaryan K, Schild HH, Kuhn W, Golubnitschaja O: How realistic are non-invasive approaches in breast cancer prediction? In / Predictive Diagnostics and Personalized Treatment: Dream or Reality. Edited by: Golubnitschaja O. New York: Nova Science Publishers; 2009:433-46.
  14. Yeghiazaryan K, Cebioglu M, Braun M, Kuhn W, Schild HH, Golubnitschaja O: Noninvasive subcellular imaging in breast cancer risk assessment: construction of diagnostic windows. / Personalized Med 2011, 8:321-30. CrossRef
  15. Golubnitschaja O, Moenkemann H, Kim K, Mozaffari MS: DNA damage and expression of checkpoint genes p21(WAF1/CIP1) and 14--3 sigma in taurine-deficient cardiomyocytes. / Biochem Pharmacol 2003, 66:511-17. CrossRef
  16. Cocquyt V, Moeremans K, Annemans L, Clarys P, Van BS: Long-term medical costs of postmenopausal breast cancer therapy. / Ann Oncol 2003, 14:1057-063. CrossRef
  17. Wolstenholme JL, Smith SJ, Whynes DK: The costs of treating breast cancer in the United Kingdom: implications for screening. / Int J Technol Assess Health Care 1998, 14:277-89. CrossRef
  18. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. / N Engl J Med 2005, 353:1784-792. CrossRef
  19. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW: Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. / CA Cancer J Clin 2010, 60:99-19. CrossRef
  20. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW: Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. / Lancet 2003, 361:1405-410. CrossRef
  21. The benefits and harms of breast cancer screening: an independent review / Lancet 2012, 380:1778-786.
  22. Jorgensen KJ, Gotzsche PC: Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. / BMJ 2009, 339:b2587. CrossRef
  23. Jorgensen KJ: Mammography screening. Benefits, harms, and informed choice. / Dan Med J 2013, 60:B4614.
  24. Buist DS, Porter PL, Lehman C, Taplin SH, White E: Factors contributing to mammography failure in women aged 40-9 years. / J Natl Cancer Inst 2004, 96:1432-440. CrossRef
  25. IARC: / IARC Handbooks of Cancer Prevention: Breast Cancer Screening. Lyon: IARC Press; 2002.
  26. Heron MP, Hoyert DL, Murphy SL, Xu JQ, Kochanek KD, Tejada-Vera B: / Deaths: Final Data for 2006. National Vital Statistics Reports; Vol 57 No 14. Hyattsville: National Center for Health Statistics; 2009.
  27. Schopper D, de WC: How effective are breast cancer screening programmes by mammography? Review of the current evidence. / Eur J Cancer 2009, 45:1916-923. CrossRef
  28. Anderson BO, Yip CH, Ramsey SD, Bengoa R, Braun S, Fitch M, Groot M, Sancho-Garnier H, Tsu VD: Breast cancer in limited-resource countries: health care systems and public policy. / Breast J 2006,12(Suppl 1):S54-S69. CrossRef
  29. Anderson BO, Yip CH, Smith RA, Shyyan R, Sener SF, Eniu A, Carlson RW, Azavedo E, Harford J: Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. / Cancer 2008, 113:2221-243. CrossRef
  
• 作者单位：Manuel Debald (1) (2)
  Kristina Yeghiazaryan (2) (3)
  Melanie Cebioglu (2) (3)
  Walther Kuhn (1) (2)
  Hans H Schild (2) (3)
  Olga Golubnitschaja (2) (3)
  
  1. Department of Obstetrics and Gynaecology, Centre for Integrated Oncology, University of Bonn, Bonn, Germany
  2. Breast Cancer Research Centre, University of Bonn, Bonn, Germany
  3. Department of Radiology, Rheinische Friedrich-Wilhelms-University of Bonn, Sigmund-Freud-Str. 25, Bonn, Germany
  
• ISSN：1878-5085

文摘

Background Breast cancer is a multifactorial disease with the highest incidence rates amongst all cancer types. Further, high levels of circulating tumour cells are a characteristic of breast cancer patients demonstrating a particular predisposition to the development of breast cancer metastatic disease. Actual diagnostic approaches are frequently unable to recognise early stages of tumour development which impairs individual outcomes. In contrast, predictive and preventive risk assessment and early diagnosis may lead to full recovery after surgical resection. Recently, the authors have reported about the construction of diagnostic windows, which could influence the molecular diagnostics of breast cancer. Material and methods In a previous study, diagnostic windows for breast cancer risk assessment were analysed. Women with non-malignant breast diseases demonstrating molecular profiles similar to those of breast cancer patients were enrolled into this follow-up study. In the interviews, for patients identified as predisposed to cancer, a specialised questionnaire has been set up to characterise individual risk factors and estimate their potential impacts on cancer onset and progression. Results and conclusions By utilising the technological tool of diagnostic windows, 13 individuals have been identified demonstrating molecular profiles typical for patients diagnosed with breast cancer. The current paper summarises the analytical results and makes statements to the application of the pathology-specific molecular profiles recognised as the technological tool for improved diagnostic approach, breast cancer risk assessment and preventive health care management. The necessity to create individual patient profiles and analyse the evolution of the molecular signature is justified for advanced medical services. Expert recommendations are provided to promote further developments in the field of advanced breast cancer management.